Dr Tuba Nur Gide is a post-doctoral cancer researcher and senior scientist at the Melanoma Institute Australia and the University of Sydney, with a focus on translational immuno-oncology. Dr Gide completed her PhD at the University of Sydney in 2019, investigating biomarkers of response and resistance to anti-PD-1 immunotherapies in metastatic melanoma. Dr Gide has since secured competitive funding, including a 2024 NHMRC Investigator Grant and a 2021 Cancer Institute NSW Early Career Fellowship.

Dr Gide has published 22 peer-reviewed articles, with 9 as first or co-first author, in leading journals such as Cancer Cell, Clinical Cancer Research, and OncoImmunology (h-index 16; >3,590 citations). A landmark study published in Cancer Cell (2019), co-first authored by Dr Gide, defined immune cell populations predictive of immunotherapy outcomes and has accrued over 910 citations. This work received the 2022 Wildfire Highly Cited Publication Award at the NSW Premier’s Awards for Outstanding Cancer Research.

Currently, Dr Gide’s research focuses on developing precision immunotherapy strategies to match patients with the most effective treatment based on individual tumour immunobiology. This includes predictive tests based on mutation profiling, gene expression signatures, spatial immune profiling, and expression of alternative drug targets. These findings underpin the Personalised Immunotherapy Program (clinicaltrials.gov ID: NCT06536257), a prospective observational study designed to transform clinical trial selection and immunotherapy delivery through precision medicine.

Dr Gide is also a co-investigator on a Cancer Institute NSW Translational Program Grant (2022–2026) aiming to personalise treatment for advanced cancer patients. In recognition of her contributions, Dr Gide was named a finalist for the 2024 AAMRI Rising Star Award and has received multiple accolades including travel and education grants and the National Council of Women of NSW Australia Day Award (2017).

Dr Gide’s work has been internationally recognised through invited oral presentations at prestigious conferences including ASCO, SMR, and AMC. This research is actively shaping the future of precision immunotherapy in melanoma and beyond.